8-K: Surgery Partners Reports Q2 2026 Results, Reaffirms Guidance

Surgery Partners announced its second quarter 2026 financial results, reporting a 2.7% increase in revenue and reaffirming its full-year guidance, despite a net loss for the quarter.

Summary

• Surgery Partners reported second quarter 2026 results with revenue increasing by 2.7% to $848.9 million compared to $826.2 million in the prior year's second quarter.
• Same-facility revenues grew by 5.0% year-over-year, driven by a 4.8% increase in revenue per case, though same-facility cases saw a modest increase of 0.3%.
• The company reported a net loss attributable to Surgery Partners, Inc. of $15.0 million for the second quarter of 2026, compared to a net loss of $2.5 million in the same period of 2025.
• Adjusted EBITDA for the second quarter was $125.2 million, a decrease from $129.0 million in the second quarter of 2025.
• Full-year 2026 guidance was reaffirmed, with projected revenues between $3.35 billion and $3.45 billion and Adjusted EBITDA of at least $530 million, excluding a pending divestiture.
• Year-to-date revenues increased by 3.6% to $1,659.8 million, while year-to-date Adjusted EBITDA decreased to $227.5 million from $232.9 million in the prior year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive report. While revenue and same-facility revenue show growth, net loss and a decrease in Adjusted EBITDA compared to the prior year are concerns. Reaffirmation of guidance and strategic divestiture are positive indicators.

Positives

• Revenue increased by 2.7% to $848.9 million in Q2 2026 compared to Q2 2025.
• Same-facility revenues showed a strong increase of 5.0% in Q2 2026.
• Revenue per case increased by 4.8% in Q2 2026 on a same-facility basis.
• Full-year 2026 revenue guidance of $3.35 billion to $3.45 billion was reaffirmed.
• Full-year 2026 Adjusted EBITDA guidance of at least $530 million was reaffirmed.
• The company is pursuing a portfolio optimization strategy, including a pending divestiture of Idaho Falls facilities, to improve its financial profile.
• Approximately 190 new physicians were recruited in Q2 2026, and 330 year-to-date, indicating growth in physician partnerships.

Negatives

• Reported a net loss of $15.0 million for the second quarter of 2026, an increase from the $2.5 million net loss in Q2 2025.
• Adjusted EBITDA decreased to $125.2 million in Q2 2026 from $129.0 million in Q2 2025.
• Year-to-date Adjusted EBITDA decreased to $227.5 million from $232.9 million in the prior year.
• Cash flow from operating activities decreased to $59.3 million in Q2 2026 from $81.3 million in Q2 2025.
• The ratio of total net debt to EBITDA was approximately 4.4x at the end of Q2 2026.

Risks

• The potential sale transaction of Idaho Falls facilities may not be completed in a timely manner or at all, including risks related to obtaining necessary approvals.
• Anticipated benefits of the sale may not be realized as expected.
• The announcement or pendency of the transaction could adversely affect the market price of securities and business relationships.
• Reductions in payments from government health care programs and private insurance payors.
• Failure to maintain or develop beneficial relationships with physicians.
• Competition for physicians, nurses, strategic relationships, acquisitions, and managed care contracts.
• The impact of future legislation and other health care regulatory reform actions.
• Risks related to cybersecurity attacks or intrusions.

Future Outlook

The company reaffirms its full-year 2026 guidance, projecting revenues between $3.35 billion and $3.45 billion and Adjusted EBITDA of at least $530 million, excluding the impact of the pending divestiture of its Idaho Falls facilities. The company expects the divestiture to be accretive to Adjusted EBITDA growth on a pro forma basis.

Management Comments

• "We are pleased with our progress this quarter, which reflects disciplined execution against our key strategic priorities to support a return to growth and reinforces our conviction in our short stay surgical platform."
• "The announcement of the pending Idaho Falls transaction was a key achievement and represents an important step forward in our portfolio optimization strategy, as we take decisive actions to improve our financial profile and sharpen our strategic focus."
• "Looking ahead, we will capitalize on the structural tailwinds underpinning long-term ASC market growth, enhance operational efficiency, and thoughtfully deploy capital to deliver long-term value for our shareholders."
• "Our financial results in the second quarter demonstrate the momentum of our ongoing initiatives to improve performance, and we are reiterating full-year guidance as a result."
• "The Idaho Falls transaction, which remains subject to closing conditions including physician members and governing board approvals, will further strengthen our financial position, through improved cash conversion and deleveraging."
• "Going forward, we are committed to disciplined capital allocation to support the continued growth of our business."

Industry Context

StockSavvy.ai notes that Surgery Partners operates in the competitive short-stay surgical facility market. The company's focus on portfolio optimization and strategic divestitures aligns with industry trends of consolidation and specialization to improve financial performance and focus on core competencies.

Comparison to Industry Standards

• The filing does not provide direct comparisons to specific industry benchmarks or competitor financial results.
• The reported same-facility revenue growth of 5.0% and revenue per case growth of 4.8% for Q2 2026 should be evaluated against broader ambulatory surgery center (ASC) industry growth rates, which can vary by specialty and region.
• The Adjusted EBITDA margin of 14.7% for Q2 2026 (14.9% excluding Idaho Falls) is a key internal metric for assessing operational efficiency, but direct comparison to publicly traded peers like Envision Healthcare or Tenet Healthcare's ASC divisions would require detailed analysis of their reporting.

Legal Proceedings

• The filing mentions potential litigation related to the Idaho Falls transaction.
• It also references ongoing legal and regulatory proceedings that have been or may be brought against the company.

Stakeholder Impact

• Shareholders: The net loss and decrease in Adjusted EBITDA may negatively impact shareholder sentiment, while the reaffirmation of guidance and strategic divestiture could be viewed positively.
• Creditors: The 4.4x net debt to EBITDA ratio indicates a moderate leverage level, which could be a point of focus for creditors.
• Employees: Continued focus on operational efficiency and strategic growth may impact employment levels and roles.
• Physicians: The company's strategy includes attracting and retaining physicians, indicating their importance as stakeholders.

Next Steps

• Complete the pending divestiture of facilities in Idaho Falls.
• Continue to capitalize on structural tailwinds in the ASC market.
• Enhance operational efficiency.
• Thoughtfully deploy capital to deliver long-term value.
• Continue disciplined capital allocation to support business growth.

Key Dates

Recommendation

The company's revenue growth and reaffirmed guidance are positive, but the increase in net loss and decrease in Adjusted EBITDA compared to the prior year warrant caution. The strategic divestiture is a positive step, but its successful completion and impact on future performance remain to be seen. A 'hold' recommendation reflects a balanced view of these competing factors.

Keywords

Surgery Partners, Q2 2026, Earnings, Revenue, Adjusted EBITDA, Guidance, Divestiture, Healthcare Services